Research programme: antibacterials - PepTx

Drug Profile

Research programme: antibacterials - PepTx

Alternative Names: Anti-infectives - PepTx; Antimicrobials - PepTx; Prosep; PTX 002; PTX 005; PTX 006; PTX 007; PTX 010; SC4 - PepTx; Sepsis therapies - PepTx

Latest Information Update: 25 Mar 2008

Price : $50

At a glance

  • Originator University of Minnesota
  • Developer PepTx; University of Minnesota
  • Class Peptides; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Bacterial infections
  • Research Sepsis

Most Recent Events

  • 25 Mar 2008 Preclinical development is ongoing
  • 13 Jul 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top